Search hospitals

>

New York

>

New York

Hospital for Special Surgery

Claim this profile

New York, New York 10021

Global Leader in Osteoarthritis

Global Leader in Systemic Lupus Erythematosus

Conducts research for Systemic Sclerosis

Conducts research for Osteoarthritis Treatment Costs

Conducts research for Rheumatoid Arthritis

383 reported clinical trials

58 medical researchers

Photo of Hospital for Special Surgery in New York

Summary

Hospital for Special Surgery is a medical facility located in New York, New York. This center is recognized for care of Osteoarthritis, Systemic Lupus Erythematosus, Systemic Sclerosis, Osteoarthritis Treatment Costs, Rheumatoid Arthritis and other specialties. Hospital for Special Surgery is involved with conducting 383 clinical trials across 469 conditions. There are 58 research doctors associated with this hospital, such as Jose Rodriguez, MD, Robert Spiera, MD, Dale J Lange, MD, and Karen Onel, MD.

Area of expertise

1

Osteoarthritis

Global Leader

Hospital for Special Surgery has run 46 trials for Osteoarthritis.

2

Systemic Lupus Erythematosus

Global Leader

Hospital for Special Surgery has run 27 trials for Systemic Lupus Erythematosus. Some of their research focus areas include:

ANA positive
anti-dsDNA positive
anti-Sm positive

Top PIs

Clinical Trials running at Hospital for Special Surgery

Lupus Nephritis

Rheumatoid Arthritis

Osteoarthritis

Osteogenesis Imperfecta

Anterior Cruciate Ligament Injury

Systemic Lupus Erythematosus

Antiphospholipid Syndrome

Lupus

Scoliosis

Vasculitis

Image of trial facility.

Ianalumab + Standard Therapy

for Lupus Nephritis

This trial will test how well ianalumab injections work and how safe they are for adults with a type of kidney inflammation caused by lupus. The medication is given under the skin at regular intervals. It aims to reduce kidney inflammation by calming the immune system.

Recruiting

1 award

Phase 3

11 criteria

Image of trial facility.

Mycophenolate Mofetil

for Pediatric Lupus Nephritis

The study is a 1-year 2-part double-blinded placebo controlled 2-arm clinical trial. Treatment arms are (1) MMF dosed as per body-surface area (MMFBSA; 600mg/m2 body surface area per dose about every 12 hours) and (2) pharmacokinetically-guided precision-dosing of MMF (MMFPK; MMF dosed twice daily to achieve an area under the concentration-time curve (AUC0-12h) of MPA \>60-70 mg\*h/L. The study goal is to determine the safety and efficacy of MMFPK compared to MMFBSA for the treatment of proliferative LN in subjects 8 to \<21 years.

Recruiting

1 award

Phase 2

10 criteria

Image of trial facility.

ONT01

for Lupus

ONT01 is a drug that is being studied for the treatment of Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) and is not approved by the FDA. The purpose of this study is to better determine whether ONT01 is safe and tolerated by people with lupus nephritis or SLE. The study also looks at how the administration of ONT01 in combination with widely used treatments given for lupus, including the medication mycophenolate mofetil and others, can improve symptoms of lupus. A total of 61 participants will be enrolled in this study.

Recruiting

1 award

Phase < 1

3 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Hospital for Special Surgery?

Where is Hospital for Special Surgery located?

Who should I call to ask about financial aid or insurance network?

What insurance does Hospital for Special Surgery accept?

What awards or recognition has Hospital for Special Surgery received?